Summary

Global Artesunate Injection Market Research Report by Purity (Artesunate 0.99, Artesunate 0.98), by Application (Malaria, Severe Malaria, Cerebral Malaria, Uncomplicated Malaria, Other Applications), by End User (Hospitals, Clinics, Pharmacies, Government Institutions, Non-Governmental Organizations), by Distribution Channel (Direct Sales, Distributors and Wholesalers, Retail Pharmacies, and Online Sales), by Region (North America, Europe, APAC, South America, MEA) Forecast till 2032

Market Overview
In 2023, the global artesunate injection market generated a revenue of approximately USD 85,003,749.11. The global artesunate injection market is projected to experience with a compound annual growth rate (CAGR) of 0.9% between 2024 and 2032.
The global artesunate injection market is driven by the rising incidence of malaria, growing preference for fast-acting injectable treatments, and advancements in manufacturing and distribution. Increased awareness and educational efforts have further supported early diagnosis and treatment.
The global artesunate injection market faces several key restraints, including the high cost of treatment, limited regional availability, and regulatory hurdles that slow product approvals. Intellectual property and patent complexities further challenge market expansion, while competition from alternative antimalarial therapies poses an additional threat.
Despite these limitations, the market presents promising opportunities. The growth of telehealth services enables remote diagnosis and timely administration of artesunate injections, especially in rural and malaria-endemic regions. Public-private partnerships are also playing a vital role by increasing funding for malaria research.
The emergence of regional manufacturing hubs enhances supply chain resilience, while overall advancements in healthcare infrastructure support broader access to injectable treatments. These factors significantly impact the global artesunate injection market, influencing supply chain dynamics, shaping demand, and affecting pricing trends.

Market Segmentations
The purity type of the global artesunate injection market research comprises Artesunate 0.99 and Artesunate 0.98.
Based on the application type, the global artesunate injection market has been segmented into malaria, severe malaria, cerebral malaria, uncomplicated malaria, other applications.
In terms of end user, the global artesunate injection market is divided into hospitals, clinics, pharmacies, government institutions, non-governmental organizations.
Depending on the distribution channel, the global market has been categorized into direct sales, distributors and wholesalers, retail pharmacies, and online sales.
Based on regions, the global artesunate injection market includes north America, Europe, South America, Middle East & Africa, and Asia Pacific.

Regional Analysis
In North America, the demand for artesunate injections is largely influenced by growing awareness of malaria as a global health concern, particularly due to increased international travel to endemic regions. While malaria is not naturally present in the United States and Canada, the number of imported cases has risen, prompting a need for effective treatment options like artesunate.
Across Europe, the European Medicines Agency (EMA) has acknowledged artesunate’s effectiveness in treating severe malaria, resulting in its integration into national treatment protocols in several countries. However, strict regulatory requirements and high treatment costs continue to pose barriers to its widespread use.
In the Asia-Pacific region, the World Health Organization’s (WHO) endorsement of artesunate as the frontline treatment for severe malaria has significantly shaped national treatment policies, boosting its acceptance and usage throughout the region.
In South America, countries located within the Amazon basin, such as Brazil, Peru, and Colombia, continue to battle high malaria transmission rates. Artesunate injections have become a core component of national treatment strategies, emphasizing their importance in controlling severe cases.
Central Africa, particularly the Democratic Republic of the Congo (DRC) and surrounding nations, remains among the most severely affected by malaria, making artesunate a vital therapy in the region’s healthcare response.

Key Players
AMIVAS, Advacare Pharma, Zydus Cadila, Intas Pharmaceutical, Systacare Remedies, Lexicare Pharma, Cipla, Guilin Pharma, IPCA Laboratories, Watran Pharmaceuticals Pvt. Ltd. are the leading companies in the Global Artesunate Injection Market Research.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY ................................................................................................................. 16
2 MARKET INTRODUCTION ............................................................................................................. 18
2.1 DEFINITION .................................................................................................................................................................. 18
2.2 SCOPE OF THE STUDY .............................................................................................................................................. 18
2.3 RESEARCH OBJECTIVE ............................................................................................................................................ 18
2.4 MARKET STRUCTURE .............................................................................................................................................. 19
3 RESEARCH METHODOLOGY ........................................................................................................ 20
3.1 OVERVIEW .................................................................................................................................................................... 20
3.2 DATA FLOW .................................................................................................................................................................. 22
3.2.1 DATA MINING PROCESS ....................................................................................................................................... 22
3.3 PURCHASED DATABASE: ......................................................................................................................................... 23
3.4 SECONDARY SOURCES: ............................................................................................................................................ 24
3.4.1 SECONDARY RESEARCH DATA FLOW: ....................................................................................................................... 25
3.5 PRIMARY RESEARCH: ............................................................................................................................................... 26
3.5.1 PRIMARY RESEARCH DATA FLOW: ....................................................................................................................... 27
3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED ........................................................................................ 28
3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE ............................................................................................................. 28
3.6 APPROACHES FOR MARKET END USER ESTIMATION: ............................................................................... 29
3.6.1 REVENUE ANALYSIS APPROACH ............................................................................................................................ 29
3.6.2 DATA FORECASTING ............................................................................................................................................. 30
3.6.3 DATA FORECASTING TECHNIQUE ............................................................................................................................ 30
3.7 DATA MODELING ........................................................................................................................................................ 31
3.7.1 MICROECONOMIC FACTOR ANALYSIS: ....................................................................................................................... 31
3.7.2 DATA MODELING: ............................................................................................................................................... 32
3.8 TEAMS AND ANALYST CONTRIBUTION ........................................................................................................... 33
4 MARKET DYNAMICS ...................................................................................................................... 35
4.1 INTRODUCTION ........................................................................................................................................................... 35
4.2 DRIVERS ......................................................................................................................................................................... 37
4.2.1 INCREASING PREVALENCE OF MALARIA ..................................................................................................................... 37
4.2.2 GROWING DEMAND FOR INJECTABLE TREATMENTS ..................................................................................................... 37
4.2.3 ADVANCEMENTS IN MANUFACTURING AND DISTRIBUTION ............................................................................................. 37
4.2.4 GROWING AWARENESS AND EDUCATION .................................................................................................................. 38
4.3 RESTRAINTS ................................................................................................................................................................ 39
4.3.1 HIGH COST OF ARTESUNATE INJECTIONS ................................................................................................................... 39
4.3.2 LIMITED AVAILABILITY IN CERTAIN REGIONS ............................................................................................................... 39
4.3.3 REGULATORY CHALLENGES AND LENGTHY APPROVAL PROCESSES..................................................................................... 39
4.3.4 INTELLECTUAL PROPERTY AND PATENT ISSUES ............................................................................................................ 40
4.3.5 COMPETING ANTIMALARIAL THERAPIES ................................................................................................................... 40
4.4 OPPORTUNITY ............................................................................................................................................................. 41
4.4.1 EXPANSION OF TELEHEALTH SERVICES FOR REMOTE DIAGNOSIS AND TREATMENT ................................................................ 41
4.4.2 INCREASED PUBLIC-PRIVATE PARTNERSHIPS FOR FUNDING MALARIA RESEARCH ................................................................... 41
4.4.3 DEVELOPMENT OF COMBINATION THERAPIES TO ENHANCE TREATMENT EFFICACY .............................................................. 42
4.4.4 EMERGENCE OF REGIONAL MANUFACTURING HUBS TO BOOST SUPPLY CHAIN RESILIENCE ..................................................... 42
4.4.5 IMPACT ON OVERALL HEALTHCARE SECTOR ................................................................................................................ 42
4.4.6 IMPACT ON GLOBAL ARTESUNATE INJECTION MARKET ........................................................................................... 43
4.4.7 IMPACT ON THE SUPPLY CHAIN OF THE ARTESUNATE INJECTION MARKET .................................................... 43
4.4.8 IMPACT ON MARKET DEMAND OF ARTESUNATE INJECTION MARKET .............................................................. 43
4.4.9 IMPACT ON PRICING OF ARTESUNATE INJECTION MARKET............................................................................. 44
5 MARKET FACTOR ANALYSIS ........................................................................................................ 45
5.1 SUPPLY CHAIN ANALYSIS ..................................................................................................................................... 45
5.1.1 RAW MATERIAL SUPPLIERS ................................................................................................................................... 46
5.1.2 MANUFACTURING ................................................................................................................................................ 46
5.1.3 DISTRIBUTION AND LOGISTICS ............................................................................................................................. 46
5.1.4 RETAIL AND CONSUMPTION .................................................................................................................................. 46
5.2 PORTER’S FIVE FORCES MODEL ........................................................................................................................... 47
5.2.1 BARGAINING POWER OF SUPPLIERS ......................................................................................................................... 48
5.2.2 BARGAINING POWER OF BUYERS ............................................................................................................................ 48
5.2.3 THREAT OF NEW ENTRANTS ................................................................................................................................... 48
5.2.4 THREAT OF SUBSTITUTES ...................................................................................................................................... 48
5.2.5 INTENSITY OF RIVALRY .......................................................................................................................................... 49
6 GLOBAL ARTESUNATE INJECTION MARKET, BY PURITY......................................................... 51
6.1 INTRODUCTION ........................................................................................................................................................... 51
6.2 ARTESUNATE 0.99 ..................................................................................................................................................... 52
6.3 ARTESUNATE 0.98 ..................................................................................................................................................... 52
7 GLOBAL ARTESUNATE INJECTION MARKET, BY APPLICATION .............................................. 54
7.1 INTRODUCTION ........................................................................................................................................................... 54
7.1.1 MALARIA .......................................................................................................................................................... 56
7.1.2 SEVERE MALARIA ............................................................................................................................................... 56
7.1.3 CEREBRAL MALARIA ............................................................................................................................................. 56
7.1.4 UNCOMPLICATED MALARIA ................................................................................................................................... 56
8 GLOBAL ARTESUNATE INJECTION MARKET, BY END USER ................................................... 58
8.1 INTRODUCTION ........................................................................................................................................................... 58
8.1.1 HOSPITALS ........................................................................................................................................................ 59
8.1.2 CLINICS ............................................................................................................................................................ 59
8.1.3 PHARMACIES .................................................................................................................................................... 59
8.1.4 GOVERNMENT INSTITUTIONS .................................................................................................................................. 60
8.1.5 NON-GOVERNMENTAL ORGANIZATIONS .................................................................................................................... 60
9 GLOBAL ARTESUNATE INJECTION MARKET, BY DISTRIBUTION CHANNEL .......................... 61
9.1 INTRODUCTION ........................................................................................................................................................... 61
9.1.1 DIRECT SALES .................................................................................................................................................... 62
9.1.2 DISTRIBUTORS AND WHOLESALERS ........................................................................................................................... 62
9.1.3 RETAIL PHARMACIES ............................................................................................................................................ 62
9.1.4 ONLINE SALES .................................................................................................................................................... 63
10 GLOBAL ARTESUNATE INJECTION MARKET, BY REGION ........................................................ 64
10.1 OVERVIEW .................................................................................................................................................................... 64
10.2 NORTH AMERICA ....................................................................................................................................................... 65
10.3 EUROPE .......................................................................................................................................................................... 71
10.4 ASIA PACIFIC ............................................................................................................................................................... 74
10.5 SOUTH AMERICA ....................................................................................................................................................... 77
10.6 MIDDLE EAST & AFRICA .......................................................................................................................................... 80
11 COMPETITIVE LANDSCAPE .......................................................................................................... 83
11.1 INTRODUCTION ........................................................................................................................................................... 83
11.2 MARKET SHARE ANALYSIS, 2023 ....................................................................................................................... 83
11.3 COMPETITOR DASHBOARD..................................................................................................................................... 84
11.4 KEY DEVELOPMENTS & GROWTH STRATEGIES ............................................................................................ 85
11.4.1 LAUNCH DEVELOPMENTS ................................................................................................................................... 85
12 COMPANY PROFILES .................................................................................................................... 86
12.1 AMIVAS ......................................................................................................................................................................... 86
12.1.1 COMPANY OVERVIEW ..................................................................................................................................... 86
12.1.2 TYPES OFFERED ............................................................................................................................................. 87
12.1.3 SWOT ANALYSIS ............................................................................................................................................ 87
12.1.4 KEY STRATEGY ................................................................................................................................................... 87
12.2 ADVACARE PHARMA ............................................................................................................................................... 88
12.2.1 COMPANY OVERVIEW ..................................................................................................................................... 88
12.2.2 TYPES OFFERED ............................................................................................................................................. 89
12.2.3 SWOT ANALYSIS ............................................................................................................................................ 89
12.2.4 KEY STRATEGY ................................................................................................................................................... 90
12.3 ZYDUS CADILA ............................................................................................................................................................ 91
12.3.1 COMPANY OVERVIEW ..................................................................................................................................... 91
12.3.2 TYPES OFFERED ............................................................................................................................................. 92
12.3.3 SWOT ANALYSIS ............................................................................................................................................ 92
12.3.4 KEY STRATEGY ................................................................................................................................................... 92
12.4 INTAS PHARMACEUTICAL ..................................................................................................................................... 93
12.4.1 COMPANY OVERVIEW ..................................................................................................................................... 93
12.4.2 TYPES OFFERED ............................................................................................................................................. 94
12.4.3 SWOT ANALYSIS ............................................................................................................................................ 94
12.4.4 KEY STRATEGY ................................................................................................................................................... 94
12.5 SYSTACARE REMEDIES ........................................................................................................................................... 95
12.5.1 COMPANY OVERVIEW ..................................................................................................................................... 95
12.5.2 TYPES OFFERED ............................................................................................................................................. 95
12.5.3 SWOT ANALYSIS ............................................................................................................................................ 96
12.5.4 KEY STRATEGY ................................................................................................................................................... 96
12.6 LEXICARE PHARMA .................................................................................................................................................. 97
12.6.1 COMPANY OVERVIEW ..................................................................................................................................... 97
12.6.2 TYPES OFFERED ............................................................................................................................................. 97
12.6.3 SWOT ANALYSIS ............................................................................................................................................ 98
12.7 CIPLA .............................................................................................................................................................................. 99
12.7.1 COMPANY OVERVIEW ..................................................................................................................................... 99
12.7.2 TYPES OFFERED ............................................................................................................................................. 99
12.7.3 SWOT ANALYSIS ............................................................................................................................................ 100
12.7.4 KEY STRATEGY ................................................................................................................................................... 100
12.8 GUILIN PHARMA ........................................................................................................................................................ 101
12.8.1 COMPANY OVERVIEW ..................................................................................................................................... 101
12.8.2 TYPES OFFERED ............................................................................................................................................. 101
12.8.3 SWOT ANALYSIS ............................................................................................................................................ 102
12.9 IPCA LABORATORIES ................................................................................................................................................ 103
12.9.1 COMPANY OVERVIEW ..................................................................................................................................... 103
12.9.2 TYPES OFFERED ............................................................................................................................................. 103
12.9.3 SWOT ANALYSIS ............................................................................................................................................ 104
12.10 WATRAN PHARMACEUTICALS PVT. LTD ........................................................................................................ 105
12.10.1 COMPANY OVERVIEW ..................................................................................................................................... 105
12.10.2 TYPES OFFERED ............................................................................................................................................. 105
12.10.3 SWOT ANALYSIS ............................................................................................................................................ 106